During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

Erratum: Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial Supported in part ...

A new pilot cohort study linked immune checkpoint inhibitors with a reduction in actinic keratoses in patients undergoing ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Nivolumab was first evaluated in a ... regimens of pembrolizumab with chemotherapy in patients with ipilimumab-refractory advanced melanoma were presented (Ribas et al, 2014b).

Licensing available upon request. For more information, please contact [email protected] Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV ...

Figure 4 Cranial MRI scans of a 76-year-old patient with melanoma of the vulva. The patient had been treated with nivolumab and ipilimumab, which had been discontinued due to autoimmune hepatitis and ...